146 related articles for article (PubMed ID: 31662008)
1. Evaluation of Juvenile Animal Studies for Pediatric CNS-Targeted Compounds: A Regulatory Perspective.
van der Laan JW; van Malderen K; de Jager N; Duarte D; Egger GF; Lavergne F; Roque CG; Vieira I; Wiesner L; Carleer J
Int J Toxicol; 2019; 38(6):456-475. PubMed ID: 31662008
[TBL] [Abstract][Full Text] [Related]
2. The need for juvenile animal studies--a critical review.
Soellner L; Olejniczak K
Regul Toxicol Pharmacol; 2013 Feb; 65(1):87-99. PubMed ID: 23108189
[TBL] [Abstract][Full Text] [Related]
3. CDER Experience With Juvenile Animal Studies for CNS Drugs.
Fisher JE; Ravindran A; Elayan I
Int J Toxicol; 2019; 38(2):88-95. PubMed ID: 30739550
[TBL] [Abstract][Full Text] [Related]
4. Juvenile animal studies in the development of pediatric medicines: experience from European medicines and pediatric investigation plans.
Duarte DM; Silva-Lima B
Birth Defects Res B Dev Reprod Toxicol; 2011 Aug; 92(4):353-8. PubMed ID: 21594973
[TBL] [Abstract][Full Text] [Related]
5. Drug discrimination: A versatile tool for characterization of CNS safety pharmacology and potential for drug abuse.
Swedberg MD
J Pharmacol Toxicol Methods; 2016; 81():295-305. PubMed ID: 27235786
[TBL] [Abstract][Full Text] [Related]
6. Juvenile animal toxicity study designs to support pediatric drug development.
Cappon GD; Bailey GP; Buschmann J; Feuston MH; Fisher JE; Hew KW; Hoberman AM; Ooshima Y; Stump DG; Hurtt ME
Birth Defects Res B Dev Reprod Toxicol; 2009 Dec; 86(6):463-9. PubMed ID: 20025047
[TBL] [Abstract][Full Text] [Related]
7. Spectrum of effects detected in the rat functional observational battery following oral administration of non-CNS targeted compounds.
Redfern WS; Strang I; Storey S; Heys C; Barnard C; Lawton K; Hammond TG; Valentin JP
J Pharmacol Toxicol Methods; 2005; 52(1):77-82. PubMed ID: 15936219
[TBL] [Abstract][Full Text] [Related]
8. Use of juvenile animal studies to support oncology medicine development in children.
Duarte DM
Reprod Toxicol; 2015 Aug; 56():97-104. PubMed ID: 25998230
[TBL] [Abstract][Full Text] [Related]
9. Lack of value of juvenile animal toxicity studies for supporting the safety of pediatric oncology phase I trials.
Visalli T; Bower N; Kokate T; Andrews PA
Regul Toxicol Pharmacol; 2018 Jul; 96():167-177. PubMed ID: 29763632
[TBL] [Abstract][Full Text] [Related]
10. Juvenile animal studies and pediatric drug development: a European regulatory perspective.
Carleer J; Karres J
Birth Defects Res B Dev Reprod Toxicol; 2011 Aug; 92(4):254-60. PubMed ID: 21638754
[TBL] [Abstract][Full Text] [Related]
11. The value of juvenile animal studies "What have we learned from preclinical juvenile toxicity studies? II".
Bailey GP; Mariën D
Birth Defects Res B Dev Reprod Toxicol; 2011 Aug; 92(4):273-91. PubMed ID: 22623019
[TBL] [Abstract][Full Text] [Related]
12. Neuropathology Evaluation in Juvenile Toxicity Studies in Rodents: Comparison of Developmental Neurotoxicity Studies for Chemicals With Juvenile Animal Studies for Pediatric Pharmaceuticals.
Bolon B; Dostal LA; Garman RH
Toxicol Pathol; 2021 Dec; 49(8):1405-1415. PubMed ID: 34620000
[TBL] [Abstract][Full Text] [Related]
13. Preclinical evaluation of Trichilia catigua extracts on the central nervous system of mice.
Chassot JM; Longhini R; Gazarini L; Mello JC; de Oliveira RM
J Ethnopharmacol; 2011 Oct; 137(3):1143-8. PubMed ID: 21801825
[TBL] [Abstract][Full Text] [Related]
14. An update of juvenile animal studies in the European Union: What do the numbers say?
Hurtt ME; Engel S
Reprod Toxicol; 2015 Aug; 56():105-8. PubMed ID: 25937597
[TBL] [Abstract][Full Text] [Related]
15. Tools in the Design of Therapeutic Drugs for CNS Disorders: An up-to-date Review.
Sahu JK; Mishra AK
Curr Mol Pharmacol; 2018; 11(4):270-278. PubMed ID: 30129422
[TBL] [Abstract][Full Text] [Related]
16. Real life juvenile toxicity case studies: the good, the bad and the ugly.
De Schaepdrijver L; Rouan MC; Raoof A; Bailey GP; De Zwart L; Monbaliu J; Coogan TP; Lammens L; Coussement W
Reprod Toxicol; 2008 Sep; 26(1):54-5. PubMed ID: 18514481
[TBL] [Abstract][Full Text] [Related]
17. A nonclinical safety assessment of MnTE-2-PyP, a manganese porphyrin.
Gad SC; Sullivan DW; Crapo JD; Spainhour CB
Int J Toxicol; 2013 Jul; 32(4):274-87. PubMed ID: 23704100
[TBL] [Abstract][Full Text] [Related]
18. Juvenile Nonclinical Safety Studies in Support of Pediatric Drug Development.
Barrow PC; Schmitt G
Methods Mol Biol; 2017; 1641():25-67. PubMed ID: 28748457
[TBL] [Abstract][Full Text] [Related]
19. Neurofunctional test batteries in safety pharmacology - Current and emerging considerations for the drug development process.
Jackson SJ; Authier S; Brohmann H; Goody SMG; Jones D; Prior H; Rosch A; Traebert M; Tse K; Valentin JP; Milne A
J Pharmacol Toxicol Methods; 2019; 100():106602. PubMed ID: 31238094
[TBL] [Abstract][Full Text] [Related]
20. Juvenile Animal Testing: Assessing Need and Use in the Drug Product Label.
Baldrick P
Ther Innov Regul Sci; 2018 Sep; 52(5):641-648. PubMed ID: 29714556
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
